Last reviewed · How we verify
Late dexamethazone
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and autoimmune conditions (specific indication unclear from 'late dexamethasone' designation), Likely used as adjunctive therapy in a defined clinical protocol.
At a glance
| Generic name | Late dexamethazone |
|---|---|
| Also known as | Dexamethasone |
| Sponsor | ClinAmygate |
| Drug class | Glucocorticoid |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Inflammation |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone enters cells and binds to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory responses. The term 'late dexamethasone' likely refers to timing of administration in a specific clinical protocol rather than a distinct mechanism.
Approved indications
- Inflammatory and autoimmune conditions (specific indication unclear from 'late dexamethasone' designation)
- Likely used as adjunctive therapy in a defined clinical protocol
Common side effects
- Hyperglycemia
- Immunosuppression / increased infection risk
- Insomnia
- Mood changes
- Hypertension
- Osteoporosis (with chronic use)
Key clinical trials
- Ultrasound-Guided Erectro Spinae Plane Block Versus Stellate Ganglion Block for Patients With Upper Limb Acute Herpes Zoster Pain. (NA)
- Anosmia and / or Ageusia and Early Corticosteroid Use (PHASE4)
- Timing of Corticosteroids in COVID-19, II. Post COVID-19 Follow-up (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Late dexamethazone CI brief — competitive landscape report
- Late dexamethazone updates RSS · CI watch RSS
- ClinAmygate portfolio CI